Home About us Reports Charts News Custom Company Scan  
Report Charts News
Title Content
Life Sciences
  Metals & Minerals
Public Sector
  Finance Service
  Real Estate
Technology And Media

Tel: 0086-10-82600828
Fax: 0086-10-82601570

 Daiichi Sankyo receives approval for Silodosin in China
CreateTime:2011-09-23 Editor:qulina
Text Size:       

Singapore, Sep 22, 2011: Daiichi Sankyo announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing), has received approval from China's State Food and Drug Administration (SFDA) for silodosin, which was developed for treatment of dysuria associated with benign prostatic hyperplasia.

By inhibiting the alpha 1A-adrenergic receptor, which exists in the prostate, silodosin relieves the tension in the prostate, lessening pressure and reducing urethral resistance to treat dysuria associated with benign prostatic hyperplasia. Silodosin delivers faster efficacy compared with existing drugs, and can treat symptoms of urinary dysfunction, such as urinary difficulty, and other symptoms, including frequent urination and the sensation of incomplete bladder emptying.

Silodosin is a selective alpha 1A-adrenoceptor antagonist that was originally discovered by Kissei Pharmaceutical. It was developed by Daiichi Sankyo and Kissei Pharmaceutical in Japan and is jointly marketed under the brand name, Urief.
Daiichi Sankyo (Beijing) has the licensing rights for development, manufacture and marketing of silodosin in China. Daiichi Sankyo is committed to contributing to the improvement of quality of life for patients in China while increasing its presence there through the launch of silodosin and other innovative pharmaceuticals.

Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1